1,720,992 research outputs found
Role of coronary angiography before radiofrequency ablation in patients presenting with paroxysmal supraventricular tachycardia
No full textRole of coronary angiography before radiofrequency ablation in patients presenting with paroxysmal supraventricular tachycardia
No full textDuring episodes of paroxysmal supraventricular tachycardia (PSVT), electrocardiograms frequently show ST-segment depressions, and patients may experience typical chest pain prompting invasive coronary angiography. We evaluated 114 patients presenting with PSVT for concomitant coronary artery disease (CAD). Patients were classified as to the type of PSVT, symptoms during PSVT, and cardiovascular risk factors. Maximum heart rate, extent of ST-segment depression, and cardiac troponin levels during PSVT were recorded. Patients were subjected to exercise testing and/or coronary angiography. During PSVT, symptoms suggestive of myocardial ischemia, including chest pain (31%), ST-segment depression (61%), and elevated troponin levels (12%), were common. Sixty-seven patients (59%) underwent coronary angiography. The overall prevalence of significant CAD was found to be low (4%) and did not correlate to symptoms during tachycardia. Routine coronary angiography cannot be recommended in patients with PSVT unless routine evaluation outside episodes of tachycardia suggests the presence of significant CAD
Role of coronary angiography before radiofrequency ablation in patients presenting with paroxysmal supraventricular tachycardia
No full textDetection of intracardiac masses in patients with coronary artery disease using cardiac magnetic resonance imaging: a comparison with transthoracic echocardiography
No full textWe sought to evaluate the diagnostic accuracy of contrast-enhanced cardiac magnetic resonance (CMR) imaging for the detection of intracardiac masses and thrombus formation in patients with history of coronary artery disease (CAD) in comparison to transthoracic echocardiography (TTE) under clinical routine conditions. 171 patients with history of CAD (89 male, aged 34-89 years, median 63 +/- A 11) underwent TTE and CMR during routine clinical examinations. TTE and CMR were independently analysed regarding the presence of intracardiac thrombus formation, masses and related size, dimensions, shape and signal characteristics. TTE depicted intracavitary thrombus formation in 40/171 patients (23.4 %) and intracardiac mass in 12/171 patients (7.0 %). All masses revealed in TTE were correctly detected on CMR and confirmed by histology. However, CMR showed 15 additional thrombi and 3 additional intracardiac masses (p = 0.001) that were not seen in TTE. Patients with poor systolic function (LVEF 30 %, whereas CMR was superior when the LVEF was < 30 %. Routine TTE in patients with CAD leads to lower detection rates of intracardiac masses and thrombus formation in patients with severely impaired EF. Consequently we are missing a significant amount of clinically relevant diagnosis when only assessing patients with TTE. In patients with CAD and severely impaired LVEF, CMR should be considered as first line imaging tool to detect or rule out intracardiac masses and thrombi
Biventricular paced T-wave alternans predict ICD discharges in permanent atrial fibrillation
No full textMild to moderate renal insufficiency predicts all-cause mortality but not shocks in patients with implantable cardioverter defibrillators
No full textMild to moderate renal insufficiency predicts all-cause mortality but not shocks in patients with implantable cardioverter defibrillators
No full textBiventricular paced T-wave alternans predict ICD discharges in permanent atrial fibrillation
No full textCost-effectiveness of paclitaxel-coated balloon angioplasty for treatment of coronary restenosis in bare-metal stents
No full textPotential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension
No full textBackground: Nonadherence to drug therapy poses a significant problem in the treatment of patients with presumed resistant hypertension. It has been shown that therapeutic drug monitoring (TDM) is a useful tool for detecting nonadherence and identifying barriers to treatment adherence, leading to effective blood pressure (BP) control. However, the cost-effectiveness of TDM in the management of resistant hypertension has not been investigated. Method: A Markov model was used to evaluate life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in resistant hypertension patients receiving either TDM optimized therapy or standard best medical therapy. The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and mortality. Cost analyses were performed from a payer's perspective. Deterministic and probabilistic sensitivity analyses were conducted. Results: In the age group of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at additional costs of (sic)3854 and (sic)3922, respectively. Given a willingness-to-pay threshold of (sic)35 000 per QALY gained, the probability of TDM being cost-effective was 95% or more in all age groups from 30 to 90 years. Results were influenced mostly by the frequency of TDM testing, the rate of nonresponders to TDM, and the magnitude of effect of TDM on BP. Conclusion: Therapeutic drug monitoring presents a potential cost-effective healthcare intervention in patients diagnosed with resistant hypertension. Importantly, this finding is valid for a wide range of patients, independent of sex and age
- …
